
LABORATORY DIVISION

Patient Name	: Mr.	PSRI No.	:
Age/Gender	: 73 Yrs/Male	Bill No	:
Source	: OPD	Report Date	: 19/12/2023 4:17PM
Collection Date&Time	: 19/12/2023 3:05PM	Lab No	:
Sample Type	: SERUM	Report Status	: Final
Referred By	: Dr	Bed No/Ward	: OPD

IMMUNO CHEMISTRY

Investigation Name	Result	Unit	Bio. Ref. Range
CA 19-9 *			
CA 19-9 (Method-CMIA)	121.36 H	U/mL	< 37.00

INTERPRETATIONS:

- * The tumour associated CA19-9 reactive antigenic determinants are carried by high molecular weight glycoproteins.
- * An increase in the assay value of CA 19-9 is frequently found in pancreatic, colorectal, gastric and gall bladder cancer. The CA 19-9 assay level decreases after therapy and increases cases of relapse, residual disease and metastasis.
- * CA 19-9 is used as an additional test for the prognosis and monitoring of therapy of patients with diagnosed malignant tumours. A decrease in the CA 19-9 assay level indicate a positive response to therapy and therefore good prognosis. A constant increase in the CA 19-9 assay value often reflects evolution of the tumour and a poor response to therapy.

	CEA *		
CEA (Method-CMIA)	2.65	ng/mL	< 5.00

COMMENTS:

- * Carcinoembryonic antigen is a glycoprotein with a molecular weight of approximately 200,000 daltons.
- * CEA is produced by cells during embryonic and fetal life and production ceases at birth. A very low serum concentration can be detected in healthy individuals.
- * Increased CEA levels can be found in certain cases of cancer (colorectal, breast, lung cancer etc.) but also in non-malignant diseases. Serum CEA levels decreases after treatment and increase in the event of cancer recurrence residual disease and metastases.

****End Of Report****

**CONSULTANT
MD. BIOCHEMISTRY**

Page: 1 Of 1



Name	: Mr.	Barcode No	:
Age/Gender	: 73 YRS/Male	Reg. No	:
Referred by	: SELF	Collected On	: 08/Mar/2024 09:36 PM
Referring Centre	: Standard	Received On	: 08/Mar/2024 09:38 PM
Sample Type	: Serum	Reported On	: 09/Mar/2024 09:45AM
Collected AT	: Dehli	Report Status	: Final

IMMUNOASSAY

Test Name	Result	Unit	Biological Ref.Interval
CA- 19.9 (Pancreatic Cancer Marker)			
CA 19.9*	38.7	U/mL	<37.0

Serum, Electro Chemi Luminescent Immuno Assay

Comment:

Carbohydrate antigen or Cancer antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. An increase in the assay value of CA - 19.9 is frequently found in certain types of cancer (Pancreas, Colorectal), but also in certain non-cancerous pathologies also. The CA - 19.9 assay is used as an additional test for the prognosis & monitoring of therapy of patients with diagnosed malignant tumours. The CA - 19.9 assay level decreases after therapy & increases in cases of relapse, residual disease & metastasis.

*** End Of Report ***